FY2026 Earnings Forecast for MetaVia Issued By HC Wainwright

MetaVia Inc. (NASDAQ:MTVA – Free Report) – Research analysts at HC Wainwright issued their FY2026 earnings estimates for shares of MetaVia in a research report issued on Tuesday, November 17th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($3.07) per share for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($1.97) per share. HC Wainwright also issued estimates for MetaVia’s Q4 2026 earnings at ($0.72) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($2.28) EPS, FY2029 earnings at ($1.88) EPS and FY2030 earnings at ($1.58) EPS.

MetaVia (NASDAQ:MTVA – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Monday, October 19th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MetaVia has an average rating of “Hold” and a consensus target price of $20.00.

Read Our Latest Analysis on MetaVia

MetaVia Stock Performance

Shares of MetaVia stock opened at $1.06 on Thursday. MetaVia has a twelve month low of $0.97 and a twelve month high of $13.42. The company’s 50 day moving average is $1.42 and its 200 day moving average is $1.59.

Top MetaVia Stories

Investors following MTVA have been watching these stories:

  • Positive Sentiment: MetaVia said the final patient completed the extended 24-week Phase 1 Part 3A study of DA-1726. The company cited encouraging preliminary safety and tolerability observations; separate Part 3B interim data showed a statistically significant 68.1% placebo-adjusted reduction in liver fat. Full data are expected in Q1 2027, with a Phase 2 study planned for the second half of 2027. Article: MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
  • Positive Sentiment: HC Wainwright reiterated a “Buy” rating on MetaVia, offering some analyst support, although its earnings forecasts point to substantial ongoing losses.
  • Negative Sentiment: MetaVia received a Nasdaq notice that its stockholders’ equity was deficient, raising a compliance concern and potential risk if the company does not meet the exchange’s requirements. Article: MetaVia Receives Nasdaq Compliance Notice Over Equity Deficiency

About MetaVia

(Get Free Report)

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.

Featured Stories

Earnings History and Estimates for MetaVia (NASDAQ:MTVA)

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.